Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Research output: Contribution to journalJournal articleResearchpeer-review

  1. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

    Research output: Contribution to journalReviewResearchpeer-review

  2. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: TP53 aberration (TP53 mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). Although each TP53 aberration is considered an equal prognosticator, the prognostic value of carrying isolated (single-hit) or multiple (multi-hit) TP53 aberrations remains unclear, particularly in the context of targeted agents.

PATIENTS AND METHODS: We performed deep sequencing of TP53 using baseline samples collected from 51 TP53 aberrant patients treated with ibrutinib in a phase II study (NCT01500733).

RESULTS: We identified TP53 mutations in 43 patients (84%) and del(17p) in 47 (92%); 9 and 42 patients carried single-hit and multi-hit TP53, respectively. The multi-hit TP53 subgroup was enriched with younger patients who had prior treatments and unmutated immunoglobulin heavy-chain variable region gene status. We observed significantly shorter overall survival, progression-free survival (PFS), and time-to-progression (TTP) in patients with multi-hit TP53 compared with those with single-hit TP53. Clinical outcomes were similar in patient subgroups stratified by 2 or >2 TP53 aberrations. In multivariable analyses, multi-hit TP53 CLL was independently associated with inferior PFS and TTP. In sensitivity analyses, excluding mutations below 1% VAF demonstrated similar outcome. Results were validated in an independent population-based cohort of 112 patients with CLL treated with ibrutinib.

CONCLUSIONS: In this study, single-hit TP53 defines a distinct subgroup of patients with an excellent long-term response to single-agent ibrutinib, whereas multi-hit TP53 is independently associated with shorter PFS. These results warrant further investigations on prognostication and management of multi-hit TP53 CLL.See related commentary by Bomben et al., p. 4462.

Original languageEnglish
JournalClinical Cancer Research
Volume27
Issue number16
Pages (from-to)4531-4538
Number of pages8
ISSN1078-0432
DOIs
Publication statusPublished - 15 Aug 2021

Bibliographical note

©2021 American Association for Cancer Research.

ID: 73917006